Phase 0 trial of oral AB 224050

Trial Profile

Phase 0 trial of oral AB 224050

Phase of Trial: Phase 0

Latest Information Update: 05 Sep 2009

At a glance

  • Drugs AB 224050 (Primary)
  • Indications Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Transplant rejection
  • Focus Pharmacokinetics
  • Sponsors Active Biotech; Chelsea Therapeutics
  • Most Recent Events

    • 05 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top